Ads
related to: metoprolol vs labetalol for tachycardia disease patients symptomswexnermedical.osu.edu has been visited by 10K+ users in the past month
Search results
Results From The WOW.Com Content Network
Group of pharmaceuticals that are used to suppress abnormally fast rhythms (tachycardias), such as atrial fibrillation, supraventricular tachycardia and ventricular tachycardia. Type I (sodium channel blockers) Type Ia Ajmaline; Procainamide; Quinidine; Type Ib Lidocaine; Phenytoin; Type Ic Encainide; Flecainide; Propafenone; Type II (beta ...
Unless a pacemaker is present, beta blockers can severely depress conduction in the AV node, resulting in a reduction of heart rate and cardiac output. One should be very cautious with the use of beta blockers in tachycardia patients with Wolff-Parkinson-White Syndrome, as it can result in life-threatening arrhythmia in certain patients.
They are also contraindicated in severe asthmatics due to bronchoconstriction, and should be used cautiously in diabetics as they can mask symptoms of hypoglycemia. Agents include either cardioselectives such as acebutolol or metoprolol, or non-cardioselectives such as oxprenolol or sotalol.
The metabolism of metoprolol can vary widely among patients, often as a result of hepatic impairment [9] or CYP2D6 polymorphism. [10] Metoprolol was first made in 1969, patented in 1970, and approved for medical use in 1978. [11] [12] [13] It is on the World Health Organization's List of Essential Medicines. [14] It is available as a generic ...
Antihypertensive agents comprise multiple classes of compounds that are intended to manage hypertension (high blood pressure). Antihypertensive therapy aims to maintain a blood pressure goal of <140/90 mmHg in all patients, as well as to prevent the progression or recurrence of cardiovascular diseases (CVD) in hypertensive patients with established CVD. [2]
Postural orthostatic tachycardia syndrome (POTS) is a disorder of the autonomic nervous system, which controls body functions we often don’t think about, such as heart rate and blood pressure ...
Labetalol was the first drug created that combined both α- and β-adrenergic receptor blocking properties. It was created to potentially fix the compensatory reflex issue that occurred when blocking a single receptor subtype, i.e. vasoconstriction after blocking β-adrenergic receptors or tachycardia after blocking α-adrenergic receptors.
Landiolol, sold under the brand name Onoact among others, is a medication used for the treatment of tachycardia, atrial fibrillation, and atrial flutter. [1] [4] It is a beta-adrenergic blocker; [4] an ultra short-acting, β1-superselective intravenous adrenergic antagonist, which decreases the heart rate effectively with less negative effect on blood pressure or myocardial contractility.